US court allows Lupin, Zydus Life to expand Myrbetriq patent argument scope
Published on 05/06/2025 01:08 PM
US court allows Lupin, Zydus Life to expand Myrbetriq patent argument scopeLupin and Zydus have more ammunition to defend their at-risk launch and it reduces their financial penalty risk, Axis Capital said.By Shloka Badkar June 5, 2025, 1:08:46 PM IST (Published)2 Min ReadShares of Lupin Ltd. and Zydus Lifesciences Ltd. gained on Thursday, June 6, after a US Court allowed the two pharma companies to expand their patent argument scope on Mirabegron, the generic equivalent of Myrbetriq, a drug used to treat overactive bladder.
The Mybetriq generic is expiring in March 2030. The court has ruled it will not entertain Zydus and Lupin's request to delay the trial.
Other generics such as MSN, Ascent are also pursuing full argument scope, an Axis Capital note stated, adding that the court wants to avoid conflicting rulings on the same patent.
Lupin and Zydus have more ammunition to defend their at-risk launch and it reduces their financial penalty risk, Axis Capital said.
In 2023, both companies had dropped the 'obviousness' argument voluntarily, the note said.
Lupin and Zydus had launched the Mybetriq generic "at risk" in April 2025, which means that the drug was launched even when litigations were ongoing.
In April 2025, the US court ruled in favour of Astellas blocking Zydus and Lupin from selling generic versions, the note said.
Myrbetriq, developed and marketed by Astellas Pharma Global Development, is a prescription drug used to treat overactive bladder (OAB) — characterised by symptoms like frequent or urgent urination and urinary incontinence. It is also approved for treating neurogenic detrusor overactivity (NDO) in paediatric patients
The combined market size of the drug is $2.4 billion as of February 2024.
Shares of Lupin and Zydus Life were trading over 2% at 1,988 and 952.55 apiece around 12.35 pm.
Also Read: Railtel Corporation shares gain 4% on bagging ₹274 crore orderContinue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsLupinshare market todayzydus lifeZydus Lifesciences